2007
The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism
Nakchbandi IA, Lang R, Kinder B, Insogna KL. The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2007, 93: 967-973. PMID: 18073309, PMCID: PMC2266956, DOI: 10.1210/jc.2007-1645.Peer-Reviewed Original ResearchConceptsNuclear factor-kappaB ligandPrimary hyperparathyroidismBone lossReceptor activatorTotal femurIL-6Bone resorptionIL-6 soluble receptorMild primary hyperparathyroidismBone mineral densitySoluble receptor activatorMechanism of actionIL-6sRSRANKL levelsSerum levelsBone turnoverMineral densityCytokine systemSoluble receptorHyperparathyroidismNormal rangeSkeletal responsivenessBiochemical markersPatientsGreater risk
2002
Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism
Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 4946-4951. PMID: 12414855, DOI: 10.1210/jc.2001-011814.Peer-Reviewed Original ResearchConceptsBone lossIL-6sRTotal femurIL-6IL-6 soluble receptorPrimary hyperparathyroidism resultsYearly bone lossSubset of patientsUntreated hyperparathyroidismDisease activityPrimary hyperparathyroidismUpper tertileCytokine axisHyperparathyroidismSoluble receptorPatientsBiochemical markersClassical biochemical markersWhole groupFemurPredict rateGreater rateRecent studiesTertileGroup
1998
Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease.
Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, Costa J, Robbins R, Burrow GN, Rosai J. Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. Journal Of Clinical Oncology 1998, 16: 1158-66. PMID: 9508203, DOI: 10.1200/jco.1998.16.3.1158.Peer-Reviewed Original ResearchConceptsReverse transcription-polymerase chain reactionPeripheral bloodThyroid diseaseThyroid carcinomaBenign thyroid nodulesThyroid peroxidaseThyroid nodulesRT-PCR positivityPeripheral blood samplesDiagnosis of carcinomaTranscription-polymerase chain reactionPapillary thyroid carcinomaBenign thyroid lesionsRET/PTC1Cervical lymphInitial surgeryClinical evidenceExtrathyroid extensionNodular hyperplasiaBenign lesionsPatientsCarcinomaBlood collectionMRNA transcriptsThyroid lesions
1996
Mechanism of technetium 99m sestamibi parathyroid imaging and the possible role of p-glycoprotein
Mitchell B, Cornelius E, Zoghbi S, Murren J, Ghoussoub R, Flynn S, Kinder B. Mechanism of technetium 99m sestamibi parathyroid imaging and the possible role of p-glycoprotein. Surgery 1996, 120: 1039-1045. PMID: 8957492, DOI: 10.1016/s0039-6060(96)80052-3.Peer-Reviewed Original ResearchConceptsAbnormal parathyroid tissueParathyroid tissueP-glycoproteinGlycoprotein expressionMechanism of technetiumTreatment of recurrentAbnormal parathyroidParathyroid visualizationPersistent hyperparathyroidismParathyroid explorationConsecutive patientsParathyroid glandsHistologic examinationSestamibi uptakeThyroid glandSestamibiTechnetium sestamibiNormal thyroidMonoclonal antibodiesImmunohistochemistryTouch preparationsTissue originTissuePossible roleRapid confirmation
1992
P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma.
Flynn S, Murren J, Kirby W, Honig J, Kan L, Kinder B. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992, 112: 981-6. PMID: 1360713.Peer-Reviewed Original ResearchConceptsP-glycoprotein expressionNormal adrenal cortexAdrenocortical carcinomaP-glycoproteinMultidrug resistanceAdrenal cortexCases of ACCStage of diseaseUnrelated chemotherapeutic agentsParaffin-embedded tumorsVariety of neoplasmsEnergy-dependent efflux pumpMost tumor cellsAdjuvant chemotherapyGlycoprotein antibodiesTumor gradeImmunohistochemistry assaysSignificant chemoresistanceSmall seriesMembrane immunoreactivityChemotherapeutic agentsGlycoprotein expressionTumor cellsEfflux pumpsAntibodies
1988
Poorly differentiated ("insular") carcinoma of the thyroid gland: an aggressive subset of differentiated thyroid neoplasms.
Flynn S, Forman B, Stewart A, Kinder B. Poorly differentiated ("insular") carcinoma of the thyroid gland: an aggressive subset of differentiated thyroid neoplasms. Surgery 1988, 104: 963-70. PMID: 3194848.Peer-Reviewed Original ResearchConceptsTotal thyroidectomyInsular carcinomaDisease 1 yearMajority of patientsAggressive clinical courseExternal beam irradiationDifferentiated thyroid neoplasmsEntire neoplasmFocal recurrenceNode dissectionAggressive treatmentClinical courseFatal courseLocal recurrenceDistant metastasisInitial diagnosisDifferentiated carcinomaAggressive subsetTumor necrosisPapillary carcinomaSuch aggressive behaviorThyroid carcinomaInsular componentPatientsCarcinomaAdvances in the Diagnosis and Treatment of Pheochromocytoma
Havlik R, Cahow C, Kinder B. Advances in the Diagnosis and Treatment of Pheochromocytoma. JAMA Surgery 1988, 123: 626-630. PMID: 3282495, DOI: 10.1001/archsurg.1988.01400290112020.Peer-Reviewed Original ResearchConceptsPerioperative fluid requirementsTotal catecholamine levelsAlpha-adrenergic blockadeIntraoperative hemodynamic stabilityTreatment of pheochromocytomaManagement of pheochromocytomaDiagnosis of pheochromocytomaHemodynamic stabilityCatecholamine levelsCatecholamine excretionSelective blockadeFluid requirementsComputed tomographyPheochromocytomaPatientsPhenoxybenzamine hydrochlorideBiochemical diagnosisPrazosin hydrochlorideDiagnosisBlockadePhenoxybenzaminePrazosinSurgeryYearsExcretion